Ventricular-Vascular Interaction in Heart Failure

Barry A Borlaug, David A. Kass

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.

Original languageEnglish (US)
Pages (from-to)447-459
Number of pages13
JournalCardiology Clinics
Volume29
Issue number3
DOIs
StatePublished - Aug 2011

Fingerprint

Blood Vessels
Heart Failure
Ventricular Function
Hemodynamics
Therapeutics

Keywords

  • Preserved ejection fraction
  • Ventriculorterial stiffening
  • Verapamil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ventricular-Vascular Interaction in Heart Failure. / Borlaug, Barry A; Kass, David A.

In: Cardiology Clinics, Vol. 29, No. 3, 08.2011, p. 447-459.

Research output: Contribution to journalArticle

Borlaug, Barry A ; Kass, David A. / Ventricular-Vascular Interaction in Heart Failure. In: Cardiology Clinics. 2011 ; Vol. 29, No. 3. pp. 447-459.
@article{9f6e3fc513dc4c11b2cb83271b5a9771,
title = "Ventricular-Vascular Interaction in Heart Failure",
abstract = "Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.",
keywords = "Preserved ejection fraction, Ventriculorterial stiffening, Verapamil",
author = "Borlaug, {Barry A} and Kass, {David A.}",
year = "2011",
month = "8",
doi = "10.1016/j.ccl.2011.06.004",
language = "English (US)",
volume = "29",
pages = "447--459",
journal = "Cardiology Clinics",
issn = "0733-8651",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Ventricular-Vascular Interaction in Heart Failure

AU - Borlaug, Barry A

AU - Kass, David A.

PY - 2011/8

Y1 - 2011/8

N2 - Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.

AB - Nearly half of all patients who have heart failure have preserved ejection fraction (HFpEF). Patients who have HFpEF tend to be older, female, and hypertensive, and characteristically display increased ventricular and arterial stiffening. In this article, we discuss the pathophysiology of abnormal ventriculoarterial stiffening and how it affects ventricular function, cardiovascular hemodynamics, reserve capacity, and symptoms. We conclude by exploring how novel treatment strategies targeting abnormal ventricular-arterial interaction might prove useful in the treatment of patients who have HFpEF.

KW - Preserved ejection fraction

KW - Ventriculorterial stiffening

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=79960756306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960756306&partnerID=8YFLogxK

U2 - 10.1016/j.ccl.2011.06.004

DO - 10.1016/j.ccl.2011.06.004

M3 - Article

VL - 29

SP - 447

EP - 459

JO - Cardiology Clinics

JF - Cardiology Clinics

SN - 0733-8651

IS - 3

ER -